Cancer
Palliative care for cancer patients often relies on parenteral opioid administration, but the optimal route remains uncertain. A recent study aimed to compare the effectiveness and safety of subcutaneous (SC) versus intravenous (IV) infusion with bolus doses of morphine in a randomized controlled trial. The study involved 60 hospitalised palliative
Cancer
Researchers at Dana-Farber Cancer Institute presented findings at the American Society for Transplantation and Cellular Therapy (ASTCT) 80/20 Workshop in June 2023, where a consensus emerged on the need for simplification and streamlining of existing CAR-T REMS programs. The experts recommended replacing manufacturer-created training with treatment center-administered programs, reporting
Cancer
Scientists at Vanderbilt University have made a significant breakthrough in cancer immunotherapy by developing a modular approach to enhance the potency of systemically administered cancer treatments. By conjugating a stimulator of interferon genes (STING) agonist to anti-albumin nanobodies, researchers have created a technology that prolongs the circulation of the agonist
Cancer
Researchers at UHN have made a groundbreaking discovery in cancer research, finding a molecule called circular RNA (circRNA) that drives the transformation of specific prostate and lung cancers into more aggressive, treatment-resistant forms. The study reveals a new potential therapeutic target for neuroendocrine prostate cancer (NEPC) and small cell lung
Cancer
Researchers at Sichuan Cancer Hospital and Research Institute, along with Liaoning Cancer Hospital & Institute, are conducting a Phase 3 clinical trial to examine the effectiveness of tislelizumab combined with chemotherapy for patients with MHC Class II-positive locally advanced gastric or gastroesophageal junction adenocarcinoma. The study is inspired by previous
Cancer
Former Sky News presenter Dermot Murnaghan has shared his experiences with stage four prostate cancer, highlighting the importance of getting tested for the disease. Murnaghan, 67, attributed his delayed diagnosis to a lack of PSA testing, which he learned about privately through his production company. He emphasized the need for
Cancer
Cue Biopharma, a clinical-stage biopharmaceutical company, has reported a significant clinical update on its most advanced asset, CUE-101, which is showing promise in treating HPV-induced cancers. The company announced an additional complete response in a patient with recurrent metastatic HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101
Cancer
Cancer has long been known to compromise the immune system, affecting both the peripheral immune system and the local tumor microenvironment. Current immunotherapies have shown limited efficacy due to severe immunosuppression. However, researchers from Amrita Vishwa Vidyapeetham have made a groundbreaking discovery, developing an immunologically engineered injectable immunehydrogel (iHG) that
Cancer
The Oncolytic Virus Cancer Therapy pipeline has emerged as a significant area of focus for pharmaceutical companies, with over 120 key players actively working on developing therapies for the treatment of various cancer types. DelveInsight's report, "Oncolytic Virus Cancer Therapy Pipeline Insight, 2025," provides comprehensive insights
Cancer
Recent research findings from a study conducted by the National Cancer Institute (NCI) have shed new light on the treatment of carcinomas. The study, which was published in Future Oncology, explored the use of sacituzumab govitecan (SG), a TROP2-directed antibody-drug conjugate, in combination with atezolizumab, an immunotherapeutic agent. The research
Cancer
Researchers from Proteotype Diagnostics Ltd, in collaboration with the University of Cambridge, have made a groundbreaking discovery in the field of cancer detection and treatment monitoring. Their innovative platform, which harnesses the body's immune response, has shown unprecedented sensitivity in identifying early-stage cancers and predicting patient responses to
Cancer
The Society for Cellular Pathology Scientists of Nigeria (SCPSN) has emphasized the importance of adopting genomic testing for improved cancer diagnosis, treatment, and prevention. At the eighth International Scientific Conference/Annual General Meeting of the association in Lagos, the National President, Dr Jonathan Madukwe, called for the adoption of genomic
